Galapagos is specialized in the discovery and early development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech: four programs in development and over 30 pre-clinical candidate and discovery programs.
Galapagos has a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.
Galapagos changed its NYSE Euronext market of reference to Amsterdam on 28 March 2014. The ISIN remained BE0003818359. The Bloomberg ticker changed to GLPG NA